Your Search Results

TAVI for aortic regurgitation

20 May 2026 – From EuroPCR 2026

This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.

When transfemoral is not an option: is TAVI still possible?

20 May 2026 – From EuroPCR 2026

This session explores alternative access strategies for Transcatheter Aortic Valve Implantation (TAVI) when the transfemoral route is not feasible. It covers complex scenarios including transcaval TAVI complications, transaxillary approaches, management of extra-large annuli with peripheral artery disease, and innovative transcarotid valve-in-valve procedures.

Imaging and physiology-guided DCB strategy

20 May 2026 – From EuroPCR 2026

Delve into advanced imaging and physiology-guided drug-coated balloon (DCB) strategies for complex coronary lesions. This session presents integrated approaches combining morphology and physiology, OCT guidance, and real-world cases highlighting DCB use in multivessel disease and calcified lesions.

Imaging and physiology integration to guided PCI

20 May 2026 – From EuroPCR 2026

Discover the integration of imaging and physiological assessment in guiding percutaneous coronary intervention (PCI). This session highlights the use of multimodality diagnostics, including invasive and non-invasive techniques, to improve planning, strategy, and management of complex coronary lesions.

ACST-2 (Second asymptomatic carotid surgery trial): stenting vs. surgery for tight carotid stenosis

26 Aug 2021

Ali Nazmi Calik and Pascal Meier review this trial comparing CEA with CAS for patients with asymptomatic carotid stenosis, which was presented by Alison Halliday (Oxford, United Kingdom of Great Britain & Northern Ireland) during a Hot Line session of the ESC Congress 2021.